Exabis Library
Welcome to the e-CCO Library!
P378: Renal AA amyloidosis associated with Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P378: The outcomes of a clinical care pathway for inflammatory bowel disease surgery
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P379 Surveillance with chromoendoscopy to detect new dysplasia in inflammatory bowel disease
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P379: Comparison of real-world treatment outcomes with infliximab vs. vedolizumab in biologic-naïve patients with inflammatory bowel disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P379: Effect of upadacitinib on inflammatory markers and clinical outcomes in patients with Crohn's disease in the phase 3, U-EXCEL, U-EXCEED, and U-ENDURE studies
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P379: Inflammatory bowel disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P379: Infliximab or adalimumab: Which should be used first for Crohn’s disease? A multicentre retrospective observational study
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P379: Is febuxostat the solution for patients who develop side effects to low dose azathioprine and allopurinol co-therapy?
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P379: Trends in Colectomy Rates and Biologic use over a 30-year period: What has changed?
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P379: Variations in disease monitoring between Inflammatory Bowel Disease patients on intravenous and subcutaneous biologic agents.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P380 What is the optimal dose of thiopurinic drugs (azatioprine) in patients with inflammatory bowel disease under treatment combined with anti-TNFα (infliximab/adalimumab)?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P380: A prospective multi-centre observational cohort study assessing the effectiveness of Budesonide MMX® for mild-to-moderate ulcerative colitis
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P380: Assessment of the awareness and education of vaccination in our IBD cohort: an observational study
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P380: Changes in faecal microbiome and metabolome are more pronounced in Crohn's disease patients who adhered to the CD-TREAT diet and responded by calprotectin.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P380: Comparative study of infliximab and adalimumab induction therapy for clinical remission and mucosal healing in paediatric patients with active Crohn’s disease
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P380: Comparison of mucosal healing through segments of ileocolonic Crohn’s disease treated with biologics
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P380: Early improvement of endoscopic outcomes with risankizumab is associated with reduced hospitalisation and surgery rates in patients with Crohn’s disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P380: Risk factors for poor postoperative outcome in patients with Crohn’s disease undergoing ileocaecal resection
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P381 Use of ustekinumab in Crohn’s disease: Singapore largest single-centre experience
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P381: Adalimumab efficacy and safety by disease duration: analysis of pooled studies of Crohn's disease
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM